Tag: Health Care

Displaying 1 - 20 of 1021 results.

Pages

Filtering by content type: Report

Filtering by content type: Press Release

Following the decision earlier this month by Advocate Health Care Network and NorthShore University HealthSystem to abandon their proposed merger, the Federal Trade Commission has dismissed its case challenging the transaction before the Commission’s administrative trial process.FTC Acting...
Federal Trade Commission staff submitted a comment to the Ohio State Senate on proposed legislation that would broaden dental hygienists’ ability to work without a supervising dentist on-site, and provide for the licensure of dental therapists, a relatively new type of “mid-level” provider who...
“The FTC is delighted with today’s district court ruling, which enjoined this merger, and the parties’ subsequent decision to abandon the transaction,” said Tad Lipsky, Acting Director of the Federal Trade Commission’s Bureau of Competition. “Advocate and NorthShore’s merger would likely have...
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical, Inc. would likely be anticompetitive.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Bausch + Lomb parent company Valeant Pharmaceuticals International, Inc. illegally acquired Paragon Holdings I, Inc.
OFTACOOP, a Puerto Rico ophthalmologist cooperative, has agreed to settle Federal Trade Commission charges that its actions harmed competition. The complaint charges that  OFTACOOP – also known as Cooperativa de Médico Oftalmólogos de Puerto Rico –  unlawfully orchestrated an agreement among...
Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, have agreed to pay $100 million to settle Federal Trade Commission charges that they violated the antitrust laws when Questcor acquired the rights to a drug that threatened its...

Filtering by content type: Advocacy Filing

Filtering by content type: Blog Post

On January 18, 2017, the Commission settled its recent challenge to the 2013 acquisition by Questcor Pharmaceuticals, Inc. (subsequently acquired by Mallinckrodt plc) of rights to the drug Synacthen from Novartis AG.
Yesterday, I spoke to a group of antitrust practitioners and those involved in healthcare policy at AAI’s Healthcare Roundtable, where I discussed past and present FTC work to promote competition in healthcare markets.

Filtering by content type: Public Statement

Filtering by content type: Case

The FTC filed a complaint in federal district court charging Shire ViroPharma Inc. with violating the antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin HCl Capsules. The complaint alleges that to maintain its...
The FTC's complaint alleges that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Lidoderm.  The agreement not to market an authorized generic – often...
The FTC's administrative complaint against Impax charges that in 2010, Impax and Endo Pharmaceuticals Inc. illegally agreed that Impax would not compete by marketing a generic version of Endo’s Opana ER until January 2013. In exchange, Endo paid Impax more than $112 million.Endo...
OFTACOOP, a Puerto Rico ophthalmologist cooperative, has agreed to settle FTC charges that its actions harmed competition.  The complaint charges that  OFTACOOP – also known as Cooperativa de Médico Oftalmólogos de Puerto Rico –  unlawfully orchestrated an agreement among competing...
Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, agreed to pay $100 million to settle charges that they violated the antitrust laws when Questcor acquired the rights to a drug that threatened its monopoly in the U.S....

Pages